InnoCare Pharma
Tracked across 2 events · 17 articles · First seen Feb 09, 2026 · Last active Mar 16, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Regulatory
InnoCare Pharma's zurletrectinib (ICP-723) has been granted priority review by the China===Center for Drug Evaluation (CDE) of the China===National Medical Products Administration (NMPA) for pediatric patients. This follows its approval for adult and adolescent patients in December 2025, indicating a positive expansion of its market and potential revenue streams. The company's shares were down 4.71% on the HKSE, which might be a short-term market reaction or unrelated.
Mar 02, 2026 · 7 articles
Tech
InnoCare Pharma announced the dosing of the first healthy volunteer in a clinical trial for ICP-538, a VAV1-directed molecular glue degrader. This marks a significant step in their development of treatments for autoimmune diseases, potentially enhancing their market position and stock value.
Feb 09, 2026 · 10 articles
Jasmine Cui
CEO
↔
InnoCare Pharma
Jasmine Cui is the Co-founder, Chairwoman, and CEO of InnoCare Pharma.
China===National Medical Products Administration
regulated by
↔
InnoCare Pharma
InnoCare Pharma's drug approvals are regulated by the China===National Medical P
NEWSDESK
Track InnoCare Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard